113 institutions hold shares in Catalyst Biosciences Inc. (CBIO), with 1.01M shares held by insiders accounting for 3.24% while institutional investors hold 58.60% of the company’s shares. The shares outstanding are 30.80M, and float is at 26.27M with Short Float at 4.34%. Institutions hold 56.71% of the Float.
The top institutional shareholder in the company is Nantahala Capital Management, LLC with over 1.87 million shares valued at $11.77 million. The investor’s holdings represent 5.95% of the CBIO Shares outstanding. As of Dec 30, 2020, the second largest holder is Acuta Capital Partners LLC with 1.36 million shares valued at $8.57 million to account for 4.33% of the shares outstanding. The other top investors are Blackrock Inc. which holds 1.35 million shares representing 4.30% and valued at over $8.5 million, while Vanguard Group, Inc. (The) holds 3.14% of the shares totaling 0.98 million with a market value of $6.2 million.
Catalyst Biosciences Inc. (NASDAQ: CBIO) is -18.70% lower on its value in year-to-date trading and has touched a low of $4.05 and a high of $8.22 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CBIO stock was last observed hovering at around $4.95 in the last trading session, with the day’s gains setting it 0.18% off its average median price target of $16.00 for the next 12 months. It is also 79.48% off the consensus price target high of $25.00 offered by 5 analysts, but current levels are 65.8% higher than the price target low of $15.00 for the same period.
Currently trading at $5.13, the stock is 3.09% and -8.11% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.42 million and changing 3.64% at the moment leaves the stock -8.66% off its SMA200. CBIO registered -15.90% loss for a year compared to 6-month loss of -10.31%. The firm has a 50-day simple moving average (SMA 50) of $5.91 and a 200-day simple moving average (SMA200) of $5.82.
The stock witnessed a 3.85% gain in the last 1 month and extending the period to 3 months gives it a -10.78%, and is 3.01% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.56% over the week and 5.17% over the month.
Catalyst Biosciences Inc. (CBIO) has around 36 employees, a market worth around $151.90M and $20.90M in sales. Distance from 52-week low is 26.67% and -37.59% from its 52-week high.
Catalyst Biosciences Inc. (CBIO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Catalyst Biosciences Inc. (CBIO) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 1 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Catalyst Biosciences Inc. is expected to release its quarterly report on 08/05/2021 and quarterly earnings per share for the current quarter are estimated at -$0.64 with sales reaching $730k over the same period.The EPS is expected to grow by 36.20% this year, but quarterly earnings will post -85.30% year-over-year. Quarterly sales are estimated to shrink -95.50% in year-over-year returns.
Catalyst Biosciences Inc. (CBIO) Insider Activity
A total of 13 insider transactions have happened at Catalyst Biosciences Inc. (CBIO) in the last six months, with sales accounting for 0 and purchases happening 13 times.
Catalyst Biosciences Inc. (CBIO): Who are the competitors?
The company’s main competitors (and peers) include AstraZeneca PLC (AZN) that is trading 2.18% up over the past 12 months. AbbVie Inc. (ABBV) is 35.25% up on the 1-year trading charts. Short interest in the company’s stock has fallen -44.19% from the last report on Apr 14, 2021 to stand at a total of 1.14 million short shares sold with a short interest ratio of 3.51.